Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 3;12(1):365.
doi: 10.3390/jcm12010365.

Safety of Sirolimus in Patients with Tuberous Sclerosis Complex under Two Years of Age-A Bicenter Retrospective Study

Dominika Śmiałek  1 , Sergiusz Jóźwiak  2 , Katarzyna Kotulska  3
Affiliations

Safety of Sirolimus in Patients with Tuberous Sclerosis Complex under Two Years of Age-A Bicenter Retrospective Study

Dominika Śmiałek et al. J Clin Med. .

Abstract

Background: mTOR inhibitors are a novel pharmacotherapy recommended for subependymal giant astrocytomas, refractory epilepsy, and the treatment of the other clinical manifestations of tuberous sclerosis complex (TSC). Clinical trials on everolimus proved it to be effective and safe in children. Despite its common use in clinical practice, the research on sirolimus is limited. This study is the first to determine and assess the severity of the adverse effects (AEs) of sirolimus administered to children with TSC under two years of age.

Methods: We performed a bicenter retrospective data analysis of medical records of individuals with TSC who initiated therapy with sirolimus under the age of two.

Results: Twenty-one patients were included in the study. At least one AE was reported in all participants. The most prevalent AEs were anemia, thrombocytosis, and hyperlipidemia. Infections and mouth ulcerations, often reported in the studies on older patients, were infrequent and of mild or moderate grade.

Conclusions: Adverse effects associated with sirolimus use in infants and young children with TSC are frequent yet not life- or health-threatening. Further multicenter prospective clinical trials should determine the long-term safety of sirolimus.

Keywords: adverse effect; infant; mTOR inhibitor; safety; sirolimus; tuberous sclerosis complex.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Anemia according to the treatment duration in patients with: (a) no history of anemia prior to sirolimus treatment, (b) a history of anemia prior to sirolimus treatment.
Figure 2
Figure 2
Elevated platelet count depending on the treatment duration in patients with: (a) platelet count within normal ranges prior to sirolimus treatment, (b) thrombocytosis prior to sirolimus treatment.
Figure 3
Figure 3
Hyperlipidemia depending on the treatment duration in patients with: (a) normal lipid blood levels prior to sirolimus treatment, (b) hyperlipidemia prior to sirolimus treatment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Curatolo P., Bombardieri R., Jozwiak S. Tuberous Sclerosis. Lancet. 2008;372:657–668. doi: 10.1016/S0140-6736(08)61279-9. - DOI - PubMed
    1. Holmes G.L., Stafstrom C.E., Baraban S.C., Bertram E., Bolton P., Brooks-Kayal A., Chugani H.T., Coulter D., Crino P., Delanerolle N.C., et al. Tuberous Sclerosis Complex and Epilepsy: Recent Developments and Future Challenges. Epilepsia. 2007;48:617–630. doi: 10.1111/j.1528-1167.2007.01035.x. - DOI - PubMed
    1. Huang J., Manning B.D. The TSC1-TSC2 Complex: A Molecular Switchboard Controlling Cell Growth. Biochem. J. 2008;412:179–190. doi: 10.1042/BJ20080281. - DOI - PMC - PubMed
    1. Franz D.N. Everolimus: An MTOR Inhibitor for the Treatment of Tuberous Sclerosis. Expert. Rev. Anticancer Ther. 2011;11:1181–1192. doi: 10.1586/era.11.93. - DOI - PubMed
    1. Chu-Shore C.J., Major P., Montenegro M., Thiele E. Cyst-like Tubers Are Associated with TSC2 and Epilepsy in Tuberous Sclerosis Complex. Neurology. 2009;72:1165–1169. doi: 10.1212/01.wnl.0000345365.92821.86. - DOI - PubMed

LinkOut - more resources